Product Name: Plk4 (167-173) pT170
Product Number: PE-04AKZ99
Size: | 200 µg | | Price: | 42.00 |
| 1 mg | | $US | 84.00 |
| 5 mg | | | 185.00 |
Peptide Name: Plk4 (167-173) pT170
Product Use: Services as a blocking peptide for use with the Plk4-pT170 rabbit polyclonal antibody (Cat. No.: AB-PK780) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T170 stimulates phosphotransferase activity and interaction with STIL.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: KHY-pT-LCG
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Scientific Background: Plk4 (SAK) is a protein-serine/threonine kinase of the Other group and Plk family. It has a key function in centriole duplication through the recruitment of the centriole biogenesis proteins SASS6, CENPJ/CPAP, CCP110, CEP135, and gamma-tubulin. When overexpressed, it is able to induce centrosome amplification through the simultaneous generation of multiple procentrioles adjoining each parental centriole during S phase. It phosphorylates S151 of FBXW5 during the G1/S transition, leading to inhibit FBXW5 ability to ubiquitinate SASS6. It is involved in trophoblast differentiation by phosphorylating HAND1, leading to disrupt the interaction between HAND1 and MDFIC and activation of HAND1. It also phosphorylates CDC25C and Chk2 (CHEK2). Its central role in centriole replication indicates that it may have a possible role in tumourigenesis, as centrosome aberrations are frequently observed in tumours.